1
|
Qi S, Guo L, Liang J, Wang K, Liao Q, He S, Lyu W, Cheng Z, Wang J, Luo X, Yan X, Lu Z, Wang X, Wang Z, Chen X, Li Q. A new strategy for the treatment of Parkinson's disease: Discovery and bio-evaluation of the first central-targeting tyrosinase inhibitor. Bioorg Chem 2024; 150:107612. [PMID: 38986418 DOI: 10.1016/j.bioorg.2024.107612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Revised: 06/20/2024] [Accepted: 06/30/2024] [Indexed: 07/12/2024]
Abstract
The high level of tyrosinase leads to the generation of neuromelanin, further causing the abnormality of redox-related protein level and mediating the occurrence and development of Parkinson's disease (PD). However, the existing tyrosinase inhibitors are mostly natural product extracts or polyphenolic derivatives, which hindered them from penetrating the blood-brain barrier (BBB). Herein, we obtained a novel tyrosinase inhibitor, 2-06 (tyrosinase: monophenolase IC50 = 70.44 ± 22.69 μM, diphenolase IC50 = 1.89 ± 0.64 μM), through the structure-based screening method. The compound 2-06 presented good in vitro and in vivo safety, and can inhibit the tyrosinase and melanogenesis in B16F10. Moreover, this compound showed neuroprotective effects and Parkinsonism behavior improving function. 2-06 was proved to penetrate the BBB and enter the central nervous system (CNS). The exploration of the binding mode between 2-06 and tyrosinase provided the foundation for the subsequent structural optimization. This is the first research to develop a central-targeting tyrosinase inhibitor, which is crucial for in-depth study on the new strategy for utilizing tyrosinase inhibitors to treat PD.
Collapse
Affiliation(s)
- Shulei Qi
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Lina Guo
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Jinxin Liang
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Kaixuan Wang
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Qinghong Liao
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China; Shandong Kangqiao Biotechnology Co., Ltd, Qingdao 266033, Shandong, People's Republic of China
| | - Siyu He
- Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang 550004, China
| | - Weiping Lyu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China
| | - Zimeng Cheng
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Jiayi Wang
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Xiaojia Luo
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Xiaomei Yan
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Ziyao Lu
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Xiaohan Wang
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China
| | - Ziming Wang
- School of Pharmacy, Binzhou Medical University, Yantai 256699, Shandong, People's Republic of China
| | - Xuehong Chen
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China.
| | - Qi Li
- Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, People's Republic of China.
| |
Collapse
|
3
|
Sim J, Lanka S, Jo JW, Chaudhary CL, Vishwanath M, Jung CH, Lee YH, Kim EY, Kim YS, Hyun SS, Lee HS, Lee K, Seo SY, Viji M, Jung JK. Inhibitory Effect of Chlorogenic Acid Analogues Comprising Pyridine and Pyrimidine on α-MSH-Stimulated Melanogenesis and Stability of Acyl Analogues in Methanol. Pharmaceuticals (Basel) 2021; 14:1176. [PMID: 34832958 PMCID: PMC8622415 DOI: 10.3390/ph14111176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 11/11/2021] [Accepted: 11/14/2021] [Indexed: 11/30/2022] Open
Abstract
In continuation of studies for α-MSH stimulated melanogenesis inhibitors, we have evaluated the design, synthesis, and activity of a new series of chlorogenic acid (CGA) analogues comprising pyridine, pyrimidine, and diacyl derivatives. Among nineteen synthesized compounds, most of them (fifteen) exhibited better inhibitions of melanin formation in B16 melanoma cells. The results illustrated that a pyridine analogue 6f and a diacyl derivative 13a of CGA showed superior inhibition profiles (IC50: 2.5 ± 0.7 μM and 1.1 ± 0.1 μM, respectively) of α-MSH activities than positive controls, kojic acid and arbutin (IC50: 54 ± 1.5 μM and 380 ± 9.5 μM, respectively). The SAR studies showed that both -CF3 and -Cl groups exhibited better inhibition at the meta position on benzylamine than their ortho and para positions. In addition, the stability of diacyl analogues of CGA in methanol monitored by HPLC for 28 days indicated the steric bulkiness of acyl substituents as a key factor in their stability.
Collapse
Affiliation(s)
- Jaeuk Sim
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Srinu Lanka
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Jeong-Woong Jo
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Chhabi Lal Chaudhary
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Manjunatha Vishwanath
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Chan-Hyun Jung
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Young-Hee Lee
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
- Samjin Central Research Institute, Samjin Pharma Co., Ltd., Cheongju 28158, Korea
| | - Eun-Yeong Kim
- College of Pharmacy, Korea University, Sejong 30019, Korea; (E.-Y.K.); (K.L.)
| | - Young-Soo Kim
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Soon-Sil Hyun
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Hee-Soon Lee
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Kiho Lee
- College of Pharmacy, Korea University, Sejong 30019, Korea; (E.-Y.K.); (K.L.)
| | - Seung-Yong Seo
- Gachon Institute of Pharmaceutical Sciences, College of Pharmacy, Gachon University, Incheon 21936, Korea;
| | - Mayavan Viji
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| | - Jae-Kyung Jung
- College of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea; (J.S.); (S.L.); (J.-W.J.); (C.L.C.); (M.V.); (C.-H.J.); (Y.-H.L.); (Y.-S.K.); (S.-S.H.); (H.-S.L.)
| |
Collapse
|
4
|
Mirabile S, Vittorio S, Paola Germanò M, Adornato I, Ielo L, Rapisarda A, Gitto R, Pintus F, Fais A, De Luca L. Evaluation of 4-(4-Fluorobenzyl)piperazin-1-yl]-Based Compounds as Competitive Tyrosinase Inhibitors Endowed with Antimelanogenic Effects. ChemMedChem 2021; 16:3083-3093. [PMID: 34223697 PMCID: PMC8518915 DOI: 10.1002/cmdc.202100396] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/02/2021] [Indexed: 11/11/2022]
Abstract
There is a considerable attention for the development of inhibitors of tyrosinase (TYR) as therapeutic strategy for the treatment of hyperpigmentation disorders in humans. Continuing in our efforts to identify TYR inhibitors, we describe the design, synthesis and pharmacophore exploration of new small molecules structurally characterized by the presence of the 4-fluorobenzylpiperazine moiety as key pharmacophoric feature for the inhibition of TYR from Agaricus bisporus (AbTYR). Our investigations resulted in the discovery of the competitive inhibitor [4-(4-fluorobenzyl)piperazin-1-yl]-(3-chloro-2-nitro-phenyl)methanone 26 (IC50 =0.18 μM) that proved to be ∼100-fold more active than reference compound kojic acid (IC50 =17.76 μM). Notably, compound 26 exerted antimelanogenic effect on B16F10 cells in absence of cytotoxicity. Docking analysis suggested its binding mode into AbTYR and into modelled human TYR.
Collapse
Affiliation(s)
- Salvatore Mirabile
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Serena Vittorio
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Maria Paola Germanò
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Ilenia Adornato
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Laura Ielo
- Department of ChemistryUniversity of TurinVia P. Giuria 710125TurinItaly
| | - Antonio Rapisarda
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Rosaria Gitto
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Francesca Pintus
- Department of Life and Environment SciencesUniversity of Cagliari09042MonserratoCagliariItaly
| | - Antonella Fais
- Department of Life and Environment SciencesUniversity of Cagliari09042MonserratoCagliariItaly
| | - Laura De Luca
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| |
Collapse
|
5
|
Recent advances in the design and discovery of synthetic tyrosinase inhibitors. Eur J Med Chem 2021; 224:113744. [PMID: 34365131 DOI: 10.1016/j.ejmech.2021.113744] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Revised: 07/28/2021] [Accepted: 07/28/2021] [Indexed: 02/08/2023]
Abstract
Tyrosinase is a copper-containing metalloenzyme that is responsible for the rate-limiting catalytic step in the melanin biosynthesis and enzymatic browning. As a promising target, tyrosinase inhibitors can be used as skin whitening agents and food preservatives, thus having broad potential in the fields of food, cosmetics, agriculture and medicine. From 2015 to 2020, numerous synthetic inhibitors of tyrosinase have been developed to overcome the challenges of low efficacy and side effects. This review summarizes the enzyme structure and biological functions of tyrosinase and demonstrates the recent advances of synthetic tyrosinase inhibitors from the perspective of medicinal chemistry, providing a better understanding of the catalytic mechanisms and more effective tyrosinase inhibitors.
Collapse
|
6
|
Wu Y, Huo D, Chen G, Yan A. SAR and QSAR research on tyrosinase inhibitors using machine learning methods. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2021; 32:85-110. [PMID: 33517778 DOI: 10.1080/1062936x.2020.1862297] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Accepted: 12/07/2020] [Indexed: 06/12/2023]
Abstract
Tyrosinase is a key rate-limiting enzyme in the process of melanin synthesis, which is closely related to human pigmentation disorders. Tyrosinase inhibitors can down-regulate tyrosinase to effectively reduce melanin synthesis. In this work, we conducted structure-activity relationship (SAR) study on 1097 diverse mushroom tyrosinase inhibitors. We applied five kinds of machine learning methods to develop 15 classification models. Model 5B built by fully connected neural networks and ECFP4 fingerprints achieved the highest prediction accuracy of 91.36% and Matthews correlation coefficient (MCC) of 0.81 on the test set. The applicability domains (AD) of classification models were defined by d S T D - P R O method. Moreover, we clustered the 1097 inhibitors into eight subsets by K-Means to figure out inhibitors' structural features. In addition, 10 quantitative structure-activity relationship (QSAR) models were constructed by four machine learning methods based on 813 inhibitors. Model 6 J, the best QSAR model, was developed by fully connected neural networks with 50 RDKit descriptors. It resulted in a coefficient of determination (r 2) of 0.770 and a root mean squared error (RMSE) of 0.482 on the test set. The AD of Model 6 J was visualized by Williams plot. The models built in this study can be obtained from the authors.
Collapse
Affiliation(s)
- Y Wu
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology , Beijing, P. R. China
| | - D Huo
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology , Beijing, P. R. China
| | - G Chen
- College of Life Science and Technology, Beijing University of Chemical Technology , Beijing, China
| | - A Yan
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology , Beijing, P. R. China
| |
Collapse
|